Sibeprenlimab - Visterra
Alternative Names: Sibeprenlimab-szsi; VIS-649; VOYXACTLatest Information Update: 27 Nov 2025
At a glance
- Originator Visterra
- Class Antirheumatics; Monoclonal antibodies; Urologics
- Mechanism of Action Tumour necrosis factor ligand superfamily member 13 inhibitors
-
Orphan Drug Status
Yes - IgA nephropathy
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered IgA nephropathy
- Phase II Sjogren's syndrome
Most Recent Events
- 26 Nov 2025 Registered for IgA nephropathy in USA (SC) - First global approval
- 26 Nov 2025 Updated efficacy, adverse event and pharmacodynamimcs data from the phase III VISIONARY trial in IgA nephropathy released by Otsuka Pharmaceutical
- 24 Nov 2025 Preregistration for IgA nephropathy in China (SC) (Otsuka Pharmaceutical pipeline, November 2025)